Model systems for experimental studies: retinal ganglion cells in culture

Author(s):  
Emilie Goodyear ◽  
Leonard A. Levin
Science ◽  
1988 ◽  
Vol 239 (4845) ◽  
pp. 1293-1296 ◽  
Author(s):  
S. Lipton ◽  
M. Frosch ◽  
M. Phillips ◽  
D. Tauck ◽  
E Aizenman

2000 ◽  
Vol 853 (2) ◽  
pp. 338-343 ◽  
Author(s):  
Aline Araujo dos Santos ◽  
Elizabeth Giestal de Araujo

2020 ◽  
Vol 117 (19) ◽  
pp. 10339-10349 ◽  
Author(s):  
Tavé van Zyl ◽  
Wenjun Yan ◽  
Alexi McAdams ◽  
Yi-Rong Peng ◽  
Karthik Shekhar ◽  
...  

Increased intraocular pressure (IOP) represents a major risk factor for glaucoma, a prevalent eye disease characterized by death of retinal ganglion cells; lowering IOP is the only proven treatment strategy to delay disease progression. The main determinant of IOP is the equilibrium between production and drainage of aqueous humor, with compromised drainage generally viewed as the primary contributor to dangerous IOP elevations. Drainage occurs through two pathways in the anterior segment of the eye called conventional and uveoscleral. To gain insights into the cell types that comprise these pathways, we used high-throughput single-cell RNA sequencing (scRNAseq). From ∼24,000 single-cell transcriptomes, we identified 19 cell types with molecular markers for each and used histological methods to localize each type. We then performed similar analyses on four organisms used for experimental studies of IOP dynamics and glaucoma: cynomolgus macaque (Macaca fascicularis), rhesus macaque (Macaca mulatta), pig (Sus scrofa), and mouse (Mus musculus). Many human cell types had counterparts in these models, but differences in cell types and gene expression were evident. Finally, we identified the cell types that express genes implicated in glaucoma in all five species. Together, our results provide foundations for investigating the pathogenesis of glaucoma and for using model systems to assess mechanisms and potential interventions.


Neuroreport ◽  
2001 ◽  
Vol 12 (1) ◽  
pp. 109-112 ◽  
Author(s):  
Alfred Sholl-Franco ◽  
Keila Gisele Azevedo Figueiredo ◽  
Elizabeth Giestal de Araujo

2021 ◽  
Vol 21 ◽  
Author(s):  
Rafael Lani-Louzada ◽  
Mariana Santana Dias ◽  
Rafael Linden ◽  
Vinicius de Toledo Ribas ◽  
Hilda Petrs-Silva

: Glaucoma leads to irreversible vision loss and current therapeutic strategies are often insufficient to prevent the progression of the disease and consequent blindness. Elevated intraocular pressure is an important risk factor, but not required for the progression of glaucomatous neurodegeneration. The demise of retinal ganglion cells represents the final common pathway of glaucomatous vision loss. Still, lifelong control of intraocular pressure is the only current treatment to prevent severe vision loss, although it frequently fails despite best practices. This scenario calls for the development of neuroprotective and pro-regenerative therapies targeting the retinal ganglion cells as well as the optic nerve. Several experimental studies have shown the potential of gene modulation as a tool for neuroprotection and regeneration. In this context, gene therapy represents an attractive approach as persistent treatment for glaucoma. Viral vectors engineered to promote overexpression of a broad range of cellular factors have been shown to protect retinal ganglion cells and/or promote axonal regeneration in experimental models. Here, we review the mechanisms involved in glaucomatous neurodegeneration and regeneration in the central nervous system. Then, we point out current limitations of gene therapy platforms and review a myriad of studies that use viral vectors to manipulate genes in retinal ganglion cells, as a strategy to promote neuroprotection and regeneration. Finally, we address the potential of combining neuroprotective and regenerative gene therapies as an approach to glaucomatous neurodegeneration.


Sign in / Sign up

Export Citation Format

Share Document